Join to View Full Profile
520 Country Club RdEugene, OR 97401
Dr. Fletcher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Luke Fletcher is an oncologist based in Eugene, OR, specializing in hematologic oncology, specifically myeloid malignancies. Since 2021, I have been working at Willamette Valley Cancer Institute And Research Center. I am committed to bringing myeloid malignancy (AML, MDS, MPN) care and trials to the community. I perform research through the Sarah Cannon Research Institute, where I am a leukemia executive committee member.
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2018 - 2021
Baylor College of MedicineResidency, Internal Medicine, 2015 - 2018
Keck School of Medicine of the University of Southern CaliforniaClass of 2015
Certifications & Licensure
OR State Medical License 2018 - 2025
TX State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2023 Sep 27
- A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation Start of enrollment: 2022 Feb 28
- A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Start of enrollment: 2024 Feb 07
- Join now to see all
Publications & Presentations
PubMed
- ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.John Mascarenhas, Prithviraj Bose, Christopher Hillis, Abdulraheem Yacoub, Firas El Chaer
Acta Haematologica. 2025-03-05 - 3 citationsA phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.Sudhir Manda, Bertrand M Anz 3rd, Christopher Benton, E Randolph Broun, Habte A Yimer
Hematological Oncology. 2024-05-01 - 11 citationsGraft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations.Laura F. Newell, Jennifer Dunlap, Ken Gatter, Grover C. Bagby, Richard D. Press
American Journal of Transplantation. 2021-05-07
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
